Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder): First interim analysis of the non-interventional study PIAZA.

Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Teichmann, B., Harde, J., Hasskarl, J., 2013.

Onkologie 36 (suppl. 7)(P797), 241. doi:10.1159/000356365